Jamison “Jamie” Lynch is a founder and Managing Director at GLS. Jamie leads GLS investments in life sciences and special situations.
Jamie is a former Principal at GKC where he led the firm’s life sciences investments, including those involving patent litigation. Jamie joined GKC in 2016 and assumed management of the firm’s investments and underwriting for matters involving product development, regulatory approval, and litigation regarding medical devices, pharmaceutical products, health care and other life sciences matters. After GKC was acquired by Burford in December 2016, Jamie served as a Principal at Burford.
Prior to joining GKC, Jamie co-led the global patent litigation team at Gilead Sciences, Inc. (“Gilead”). At Gilead, Jamie led global litigation strategy and execution, including Hatch-Waxman litigation, for products representing $19 billion in annual revenue.
Prior to joining Gilead, Jamie was a partner at Mayer Brown, where he was actively involved in pharmaceutical patent litigation, patent prosecution and due diligence in the firm’s Chicago and Frankfurt offices. Before Mayer Brown, Jamie represented generic companies in Hatch-Waxman disputes at Schiff Hardin and Leydig, Voit & Mayer. Jamie holds a J.D. and B.S. (mechanical engineering, with additional significant coursework in chemistry) from the University of Wisconsin.
